Week In Review: BeiGene Raises $97 Million For Cancer Drugs

BeiGene, a Beijing biopharma focused on developing novel targeted and immuno-oncology cancer therapies, completed a $97 million fundraising.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.